You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
LabCorp also entered into a lab services relationship with the healthcare system, through which it will provide reference testing for all the system's facilities and clinics.
Healthcare providers need multiplexed tests that can differentiate the flu from the coronavirus so they can treat patients quickly and appropriately.
Saying pooled testing for coronavirus was not for diagnostic purposes, Cigna had said it wouldn't reimburse for the method, but it plans to change its policy.
Lab firms are acquiring equipment and implementing approaches like pooled testing, but it remains unclear if this will be enough to meet a fall surge.
News items for the week of July 27, 2020.
The inability to get COVID-19 test kits and the reagents to run the tests was especially problematic as 58 percent of labs cited such an issue.
The company reported $2.77 billion in revenues on the quarter, down from $2.88 billion in Q2 2019 but above the consensus Wall Street estimate of $2.5 billion.
The FDA reissued the EUA after analyzing LabCorp data that showed the test could detect SARS-CoV-2 in a general asymptomatic population.
The coming uptick in flu and other respiratory viruses will likely complicate the diagnosis of COVID-19 even as labs continue to struggle with capacity.
News items for in vitro diagnostics industry for the week of July 20, 2020.